Botox maker Allergan plc (NYSE: AGN), which has agreed to be bought by AbbVie Inc (NYSE: ABBV) for $63 billion, reported Tuesday ahead of the open with higher third-quarter revenue and an adjusted loss that was wider than expected.
The company said its pending acquisition by AbbVie is on schedule.
Botox Boost For Top Line
Allergan said its third-quarter total net revenue climbed 3.6% year-over-year to $4.05 billion, ahead of the $3.88-billion consensus estimate.
Non-GAAP net revenues improved from $3.91 billion to $4.03 billion.
The company attributed the year-over-year growth to strong sales of the antipsychotic drug Vraylar, Botox Cosmetic, Juvederm, Botox Therapeutic, Ozurdex and Lo Loestrin. Vraylar sales grew 70% and U.S. Botox Cosmetic sales grew 10%.
Loss Wider Than Street Forecast
The net loss per share widened from 11 cents to $2.40. The non-GAAP net income per share remained flat at $4.25, higher than the Street forecast of $4.22.
Allergan upwardly revised its 2019 guidance and said it expects total non-GAAP net revenue of $15.6 billion to $15.8 billion versus the previous guidance of $15.4 billion to $15.6 billion.
The company increased the low end of its loss per share estimate from a loss of $12.03 to a loss of $14.98 per share, but maintained the upper end of the range at a loss per share of $16.55.
Deal Itinerary Intact
In an update on its pending merger with AbbVie, Allergan said its shareholders voted Oct. 14 to approve the deal. The company also said it has received a second request from the FTC.
Both AbbVie and Allergan expect the deal to close in early 2020, according to Allergan.
Allergan shares were down 0.25% at $178.36 at the time of publication Tuesday.
The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment
The Week Ahead In Biotech: Smid-Cap Earnings Deluge, SITC Conference In The Spotlight
Photo courtesy of Allergan.
See more from Benzinga
- Attention Biotech Investors: Mark Your Calendar For These November PDUFA Dates
- The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek's Mixed Clinical Readout, CareDx Slips On Guidance
- The Daily Biotech Pulse: Agile Receives Favorable Adcom Verdict, Merit Medical Tumbles On Earnings, 2 Biotechs To Debut
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.